Metronidazole Vitamin B6 Tablets

Metronidazole has a strong antibacterial effect on most anaerobic bacteria, but has no effect on aerobic bacteria and facultative anaerobes. The antibacterial spectrum includes Bacteroides fragilis and other Bacteroides, Fusobacterium, Clostridium perfringens, Eubacterium, Veillonella, Peptococcus and Peptostreptococcus. Actinomycetes, Lactobacillus and Propionibacterium are resistant to this product. Its bactericidal concentration is slightly higher than the inhibitory concentration. In addition, it has a strong killing effect on amoeba and Trichomonas. The bactericidal mechanism of metronidazole has not been fully elucidated. The nitroreductase of anaerobic bacteria plays an important role in the energy metabolism of sensitive strains. The nitro group of this product is reduced to a cytotoxin, which acts on the DNA metabolism process of bacteria and promotes cell death. Resistant bacteria often lack nitroreductase and are therefore resistant to metronidazole. Vitamin B6 can reduce the adverse reactions of metronidazole.

Each tablet contains 0.20g of metronidazole and 0.02g of vitamin B6.

This product is an off-white tablet or film-coated tablet, which appears off-white or slightly yellow after removing the film coating.

It is used for various anaerobic infections: such as septicemia, endocarditis, empyema, lung abscess, abdominal infection, gynecological infection, bone and joint infection, meningitis, brain abscess, skin and soft tissue infection, antibiotic-related enteritis caused by Clostridium difficile, Helicobacter pylori-related gastritis or peptic ulcer, periodontal infection and Gardner bacteria vaginitis, etc. It can also be used for intestinal and extraintestinal amebiasis, vaginal trichomoniasis, balantidiasis, dracunculiasis, giardiasis, etc.

Oral administration: 1-2 tablets each time, 3 times a day, for 7 days or longer. The maximum daily oral dose should not exceed 20 tablets.

The most serious adverse reactions of this product are epileptic seizures and peripheral neuropathy at high doses, the latter of which is mainly manifested as numbness and paresthesia of the extremities. In some cases, long-term use may cause persistent peripheral neuropathy. Other common adverse reactions include: 1. Gastrointestinal reactions, such as nausea, loss of appetite, vomiting, diarrhea, abdominal discomfort, taste changes, dry mouth, metallic taste in the mouth, etc.; 2. Reversible neutropenia; 3. Allergic reactions, rash, urticaria, etc.; 4. Central nervous system symptoms, such as headache, dizziness, syncope, ataxia and mental confusion; 5. Local reactions such as thrombophlebitis; 6. Others include fever, vaginal candidal infection, and dark urine, which may be caused by the metabolites of this product and seem to have no clinical significance.

1. Patients with a history of allergy to this product or azole drugs are prohibited from using this product. 2. Patients with active central nervous system diseases are prohibited from using this product. 3. Pregnant and lactating women are prohibited from using this product.

Precautions for children: Children should use with caution. Precautions for pregnancy and lactation: This product can pass through the placenta and quickly enter the fetal circulation. This product can also be secreted into breast milk. Animal experiments show that this product has a carcinogenic effect on young mice, so pregnant and lactating women are prohibited. Precautions for the elderly: 1. Due to decreased liver function, the pharmacokinetics of this product will change when used in the elderly, and blood drug concentrations need to be tested. 2. The maximum daily oral dose should not exceed 20 tablets.

1 This product can inhibit the metabolism of warfarin and other oral anticoagulants, enhance their effects, and cause the prothrombin time to be prolonged. 2 The simultaneous use of drugs that induce liver microsomal enzymes, such as phenytoin sodium and phenobarbital, can enhance the metabolism of this product, reduce the blood concentration, and slow down the excretion of phenytoin sodium. 3 The simultaneous use of drugs that inhibit the activity of liver microsomal enzymes, such as cimetidine, can slow down the metabolism and excretion of this product in the liver, and prolong the serum half-life of this product. The dosage should be adjusted according to the results of blood drug concentration determination. 4 This product interferes with the metabolism of disulfiram. The combination of the two can cause mental symptoms after drinking. Therefore, those who have used disulfiram within 2 weeks should not use this product again.

Keep away from light and store in sealed container.

0.2 g Metronidazole 20 mg Vitamin B6

24 months

Panshi Jukang Pharmaceutical Co., Ltd.

• Founded in:

  2014-09-25

• Address:

  No. 777, Yinglian Street, Panshi City, Jilin City, Jilin Province

• Tax NO.:

  91220284316621591H

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view